{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:49:03Z","timestamp":1750308543406,"version":"3.41.0"},"reference-count":21,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1536\/ihj.17-177","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T22:13:48Z","timestamp":1495491228000},"page":"307-309","source":"Crossref","is-referenced-by-count":2,"title":["New Insights Into Tolvaptan Treatment and the Renin-Angiotensin-Aldosterone System"],"prefix":"10.1536","volume":"58","author":[{"given":"Keisuke","family":"Kida","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ponikowski P, Voors AA, Anker SD, <i>et al<\/i>. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yamamura Y, Nakamura S, Itoh S, <i>et al<\/i>. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-7.","DOI":"10.1016\/S0022-3565(24)37873-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev 2007; 25: 1-13. (Review)","DOI":"10.1111\/j.1527-3466.2007.00001.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J 2014; 78: 844-52.","DOI":"10.1253\/circj.CJ-66-0093"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kida K, Shibagaki Y, Tominaga N, <i>et al<\/i>. Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study. Clin Pharmacokinet 2015; 54: 273-84.","DOI":"10.1007\/s40262-014-0194-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tominaga N, Kida K, Matsumoto N, <i>et al<\/i>. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics\/pharmacodynamics study. Clin Nephrol 2015; 84: 29-38.","DOI":"10.5414\/CN108457"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jujo K, Saito K, Ishida I, <i>et al<\/i>. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 2016; 3: 177-88.","DOI":"10.1002\/ehf2.12088"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Adachi S, Miura S, Shiga Y, <i>et al<\/i>. Effects of tolvaptan with or without the pre-administration of renin-angiotensin system blockers in hospitalized patients with acute decompensated heart failure. Int Heart J 2017; 58: 385-92.","DOI":"10.1536\/ihj.16-220"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kadota M, Ise T, Yagi S, <i>et al<\/i>. Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin. Int Heart J 2016; 57: 461-5.","DOI":"10.1536\/ihj.15-491"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Imamura T, Kinugawa K, Fujino T, <i>et al<\/i>. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240-9.","DOI":"10.1253\/circj.CJ-14-0244"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Imamura T, Kinugawa K, Minatsuki S, <i>et al<\/i>. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 2013; 77: 1208-13.","DOI":"10.1253\/circj.CJ-12-1328"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Imamura T, Kinugawa K. Urine aquaporin-2: a promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure. Int J Mol Sci 2016; 17: E105. (Review)","DOI":"10.3390\/ijms17010105"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nitta D. Predictors for tolvaptan treatment and future perspectives. Int Heart J 2016; 57: 391-2.","DOI":"10.1536\/ihj.16-256"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan Heart 2016; 102: 1342-7. (Review)","DOI":"10.1136\/heartjnl-2014-306775"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. McMurray JJ, Packer M, Desai AS, <i>et al<\/i>. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15: 1062-73.","DOI":"10.1093\/eurjhf\/hft052"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Konstam MA, Gheorghiade M, Burnett JC Jr, <i>et al<\/i>. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.","DOI":"10.1001\/jama.297.12.1319"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hauptman PJ, Burnett J, Gheorghiade M, <i>et al<\/i>. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013; 19: 390-7.","DOI":"10.1016\/j.cardfail.2013.04.001"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25: S57-65.","DOI":"10.1007\/s10557-011-6349-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hanatani A, Shibata A, Kitada R, <i>et al<\/i>. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels 2017; 32: 287-94.","DOI":"10.1007\/s00380-016-0872-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Katsumata M, Hirawa N, Sumida K, <i>et al<\/i>. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clin Exp Nephrol 2017. (in press)","DOI":"10.1007\/s10157-016-1379-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kinugawa K, Inomata T, Sato N, <i>et al<\/i>. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance Int Heart faiLurE (SMILE study). Int Heart J 2015; 56: 137-43.","DOI":"10.1536\/ihj.14-332"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/3\/58_17-177\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T19:00:24Z","timestamp":1750273224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/3\/58_17-177\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.17-177","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"type":"print","value":"1349-2365"},{"type":"electronic","value":"1349-3299"}],"subject":[],"published":{"date-parts":[[2017]]}}}